Nu Skin Enterprises Announces 2024 Annual Meeting of Stockholders

Ticker: NUS · Form: DEF 14A · Filed: Apr 12, 2024 · CIK: 1021561

Nu Skin Enterprises, Inc. DEF 14A Filing Summary
FieldDetail
CompanyNu Skin Enterprises, Inc. (NUS)
Form TypeDEF 14A
Filed DateApr 12, 2024
Risk Levellow
Pages16
Reading Time19 min
Sentimentneutral

Sentiment: neutral

Topics: proxy statement, annual meeting, executive compensation, incentive plan, auditor ratification

TL;DR

<b>Nu Skin Enterprises will hold its Annual Meeting on June 5, 2024, to vote on director elections, executive compensation, incentive plans, and auditor ratification.</b>

AI Summary

NU SKIN ENTERPRISES, INC. (NUS) filed a Proxy Statement (DEF 14A) with the SEC on April 12, 2024. Annual Meeting scheduled for June 5, 2024, at 11:00 a.m. MDT in Provo, Utah. Stockholders will vote on electing eight directors. An advisory vote to approve executive compensation is on the agenda. Approval of the 2024 Omnibus Incentive Plan is a key proposal. PricewaterhouseCoopers LLP is proposed for ratification as the independent auditor for 2024.

Why It Matters

For investors and stakeholders tracking NU SKIN ENTERPRISES, INC., this filing contains several important signals. The meeting will determine the composition of the Board of Directors and approve compensation structures, directly impacting corporate governance and shareholder alignment. Approval of the 2024 Omnibus Incentive Plan is crucial for retaining and motivating key employees, which can influence future performance and innovation.

Risk Assessment

Risk Level: low — NU SKIN ENTERPRISES, INC. shows low risk based on this filing. This filing is a routine proxy statement for an annual meeting and does not contain significant new financial or operational information that would alter the company's risk profile.

Analyst Insight

Review the proposed director nominees and executive compensation details to assess alignment with shareholder interests and company strategy.

Key Numbers

  • 8 — Directors to be elected (Annual Meeting agenda item)
  • 2024 — Omnibus Incentive Plan (Proposed plan for approval)
  • 2024 — Independent registered public accounting firm (PricewaterhouseCoopers LLP proposed for ratification)
  • June 5, 2024 — Annual Meeting Date (Date of the Annual Meeting of Stockholders)
  • April 8, 2024 — Record Date (Date for determining stockholders entitled to vote)

Key Players & Entities

  • NU SKIN ENTERPRISES, INC. (company) — Registrant
  • PricewaterhouseCoopers LLP (company) — independent registered public accounting firm
  • GREGORY BELLISTON (person) — business and mail address contact

FAQ

When did NU SKIN ENTERPRISES, INC. file this DEF 14A?

NU SKIN ENTERPRISES, INC. filed this Proxy Statement (DEF 14A) with the SEC on April 12, 2024.

What is a DEF 14A filing?

A DEF 14A is a definitive proxy statement sent to shareholders before annual meetings, covering executive compensation, board nominations, and shareholder votes. This particular DEF 14A was filed by NU SKIN ENTERPRISES, INC. (NUS).

Where can I read the original DEF 14A filing from NU SKIN ENTERPRISES, INC.?

You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by NU SKIN ENTERPRISES, INC..

What are the key takeaways from NU SKIN ENTERPRISES, INC.'s DEF 14A?

NU SKIN ENTERPRISES, INC. filed this DEF 14A on April 12, 2024. Key takeaways: Annual Meeting scheduled for June 5, 2024, at 11:00 a.m. MDT in Provo, Utah.. Stockholders will vote on electing eight directors.. An advisory vote to approve executive compensation is on the agenda..

Is NU SKIN ENTERPRISES, INC. a risky investment based on this filing?

Based on this DEF 14A, NU SKIN ENTERPRISES, INC. presents a relatively low-risk profile. This filing is a routine proxy statement for an annual meeting and does not contain significant new financial or operational information that would alter the company's risk profile.

What should investors do after reading NU SKIN ENTERPRISES, INC.'s DEF 14A?

Review the proposed director nominees and executive compensation details to assess alignment with shareholder interests and company strategy. The overall sentiment from this filing is neutral.

How does NU SKIN ENTERPRISES, INC. compare to its industry peers?

Nu Skin Enterprises operates in the direct selling industry, primarily focusing on skincare and nutritional products.

Are there regulatory concerns for NU SKIN ENTERPRISES, INC.?

The filing is made under Section 14(a) of the Securities Exchange Act of 1934, which governs the solicitation of proxies from shareholders.

Risk Factors

  • Compliance with Securities Laws [low — regulatory]: The company must comply with SEC regulations regarding proxy solicitations and disclosures, including this DEF 14A filing.

Industry Context

Nu Skin Enterprises operates in the direct selling industry, primarily focusing on skincare and nutritional products.

Regulatory Implications

The filing is made under Section 14(a) of the Securities Exchange Act of 1934, which governs the solicitation of proxies from shareholders.

What Investors Should Do

  1. Review the list of director nominees and their qualifications.
  2. Analyze the details of the proposed 2024 Omnibus Incentive Plan.
  3. Examine the advisory vote on executive compensation and the rationale provided.

Key Dates

  • 2024-06-05: Annual Meeting of Stockholders — Vote on director elections, executive compensation, incentive plan, and auditor ratification.
  • 2024-04-08: Record Date — Determines which stockholders are eligible to vote at the Annual Meeting.
  • 2024-04-12: Filing Date — Date this Definitive Proxy Statement (DEF 14A) was filed with the SEC.

Year-Over-Year Comparison

This is a DEF 14A filing, which is a standard annual proxy statement and does not represent a change from previous filings in terms of format or purpose.

Filing Stats: 4,668 words · 19 min read · ~16 pages · Grade level 11.4 · Accepted 2024-04-12 16:49:19

Filing Documents

Executive Compensation: Compensation

Executive Compensation: Compensation Discussion and Analysis 19 Executive Summary 19 Compensation Overview 24 Components of Compensation 25 Process for Determining Compensation 32 Other Compensation-Related Governance 34 Compensation and Human Capital Committee Report 36 Executive Compensation Tables and Accompanying Narrative 37 Other Compensation Information 48 Equity Compensation Plan Information 48 CEO Pay Ratio Information 48 Pay Versus Performance 49 Proposal 2: Advisory Vote To Approve Our Executive Compensation 53 Proposal 3: Approval of 2024 Omnibus Incentive Plan 55 Proposal 4: Ratification of Selection of Independent Registered Public Accounting Firm 65 Fees to Independent Registered Public Accountants 65 Audit and Non-Audit Services Pre-Approval Policy 66 Audit Committee Report 67 Certain Relationships and Related-Person Transactions 68 Stock Ownership Information 69 Stockholder Proposals for 2025 Annual Meeting 71 Householding 71 Cautionary 71 Other Matters 72 Appendix A: 2024 Omnibus Incentive Plan A-1 Form of Proxy Card PROXY SOLICITATION OF PROXIES The accompanying proxy is solicited on behalf of the Board of Directors of Nu Skin Enterprises, Inc. ("Nu Skin," "we," "us," or "the company") for use at the Annual Meeting of Stockholders (the "Annual Meeting") on June 5, 2024 at 11:00 a.m., Mountain Daylight Time, and at any adjournment or postponement thereof. The Annual Meeting will be held at our corporate offices, 75 West Center Street, Provo, Utah 84601. At the Annual Meeting, you will be asked to consider and vote on the following matters, which are more fully described in this proxy statement: 1. To elect the eight directors named in this proxy statement; 2. To hold an advisory vote to approve our executive compensation; 3. To approve our 2024 Omnibus Incentive Plan; 4. To ratify the selection o

View Full Filing

View this DEF 14A filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.